Rapport Therapeutics, Inc. (RAPP)

Rapport Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023
Net Income	-107.28	-111.48	-78.31	-34.79
Depreciation & Amortization	1	1.02	0.84	0.11
Stock-Based Compensation	21.78	18.86	10.24	3.53
Other Adjustments	1.03	0.64	4.82	1.32
Change in Receivables	-0.06	-	-	-
Changes in Accounts Payable	4.34	2.22	-0.35	0.86
Changes in Accrued Expenses	2.34	6.17	0.37	5.38
Changes in Other Operating Activities	-3.45	-4.88	-2.44	-3.58
Operating Cash Flow	-80.3	-87.47	-64.83	-27.18
Capital Expenditures	-0.41	-0.62	-2.41	-1.64
Purchases of Investments	-341.92	-354.78	-377.53	-77.22
Proceeds from Sale of Investments	171.77	167.93	209.8	-
Investing Cash Flow	-170.56	-187.47	-170.14	-78.86
Issuance of Common Stock	1.76	270.79	157.71	0.05
Repurchase of Common Stock	-0.01	-0	-	-0
Net Common Stock Issued (Repurchased)	1.75	270.79	157.71	0.05
Issuance of Preferred Stock	-	-	63.91	145.22
Net Preferred Stock Issued (Repurchased)	-	-	63.91	145.22
Other Financing Activities	-0.34	-	-	-0.13
Financing Cash Flow	271.31	270.79	221.63	145.14
Net Cash Flow	20.45	-4.16	-13.34	39.1
Free Cash Flow	-80.71	-88.09	-67.23	-28.82
FCF Margin	-403.54%	-	-	-
Free Cash Flow Per Share	-1.93	-2.26	-3.24	-19.14
Levered Free Cash Flow	-103.46	-107.58	-82.29	-33.66
Unlevered Free Cash Flow	-118.39	-121.2	-87.04	-35.06

Updated May 7, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q